Literature DB >> 32596797

The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer.

Tairin Uchino1,2, Akira Ouchi3, Koji Komori1, Takashi Kinoshita1, Taihei Oshiro1, Tsuyoshi Sano2, Yasuhiro Shimizu1.   

Abstract

PURPOSE: The aim of this study was to investigate the predictive relevance of tumor sidedness on surgical resection after recurrence by evaluating the treatment outcomes after primary resection and recurrence in patients with localized colon cancer (CC).
METHODS: A total of 735 consecutive patients who underwent curative resection for Stage I-III CC from 1997 to 2013 were categorized as having either right- or left-sided CC, and survival after primary surgery and after recurrence were analyzed.
RESULTS: A total of 104 patients (14.1%) developed recurrence, 94 of which were in a single organ, and 59 patients underwent curative resection. For recurrence from both sides of the colon, a significantly better 5-year overall survival (OS) was experienced by patients who underwent curative resection compared to those who received palliative treatment (right: 42.2% vs not reached, respectively; P < 0.001; left: 71 vs 15.9%, respectively; P < 0.001). Meanwhile, a still worse OS was observed in patients with curative resection for recurrent right-sided CC compared to those with resection for recurrent left-sided CC (5-year: 42.2 vs 71%; P = 0.03).
CONCLUSION: Surgical resection undoubtedly improved survival after recurrence, however, patients with surgical resection for recurrent right-sided CC tended to have a worse prognosis.

Entities:  

Keywords:  Colon cancer; Recurrence; Sidedness

Mesh:

Year:  2020        PMID: 32596797     DOI: 10.1007/s00595-020-02060-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

1.  Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases.

Authors:  Suguru Yamashita; Kristoffer Watten Brudvik; Scott E Kopetz; Dipen Maru; Callisia N Clarke; Guillaume Passot; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2018-03       Impact factor: 12.969

2.  Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Authors:  Julien Taieb; Hampig Raphael Kourie; Jean-François Emile; Karine Le Malicot; Ralyath Balogoun; Josep Tabernero; Enrico Mini; Gunnar Folprecht; Jean-Luc Van Laethem; Claire Mulot; Olivier Bouché; Thomas Aparicio; Pierre Michel; Josef Thaler; John Bridgewater; Eric Van Cutsem; Géraldine Perkins; Come Lepage; Ramon Salazar; Pierre Laurent-Puig
Journal:  JAMA Oncol       Date:  2018-07-12       Impact factor: 31.777

3.  Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma.

Authors:  Koichi Yagi; Hirokazu Takahashi; Kiwamu Akagi; Keisuke Matsusaka; Yasuyuki Seto; Hiroyuki Aburatani; Atsushi Nakajima; Atsushi Kaneda
Journal:  Am J Pathol       Date:  2011-11-21       Impact factor: 4.307

Review 4.  Different treatment strategies and molecular features between right-sided and left-sided colon cancers.

Authors:  Hong Shen; Jiao Yang; Qing Huang; Meng-Jie Jiang; Yi-Nuo Tan; Jian-Fei Fu; Li-Zhen Zhu; Xue-Feng Fang; Ying Yuan
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

6.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Authors:  D Arnold; B Lueza; J-Y Douillard; M Peeters; H-J Lenz; A Venook; V Heinemann; E Van Cutsem; J-P Pignon; J Tabernero; A Cervantes; F Ciardiello
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

7.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

8.  Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution.

Authors:  Konosuke Moritani; Hirotoshi Hasegawa; Koji Okabayashi; Yoshiyuki Ishii; Takashi Endo; Yuko Kitagawa
Journal:  Surg Today       Date:  2013-10-16       Impact factor: 2.549

9.  Association between Primary Tumor Location and Prognostic Survival in Synchronous Colorectal Liver Metastases after Surgical Treatment: A Retrospective Analysis of SEER Data.

Authors:  Zheng Wang; Xiangyu Wang; Ze Zhang; Xuan Wang; Mo Chen; Lu Lu; Wenwei Zhu; Jubo Zhang; Huliang Jia; Jinhong Chen
Journal:  J Cancer       Date:  2019-02-26       Impact factor: 4.207

10.  Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score.

Authors:  Elisabeth Gasser; Eva Braunwarth; Marina Riedmann; Benno Cardini; Nikolaus Fadinger; Jaroslav Presl; Eckhard Klieser; Philipp Ellmerer; Aurélien Dupré; Katsunori Imai; Hassan Malik; Hideo Baba; Hanno Ulmer; Stefan Schneeberger; Dietmar Öfner; Adam Dinnewitzer; Stefan Stättner; Florian Primavesi
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

View more
  1 in total

1.  Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer.

Authors:  Wenbin Cao; Bo Zhang; Yang Liu
Journal:  Biomed Res Int       Date:  2022-06-08       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.